Pembrolizumab combined with chemotherapy for advanced or metastatic non-small cell lung cancer with low PD-L1 expression: a systematic review and meta-analysis of randomized controlled trials
{{output}}
Introduction: Pembrolizumab plus chemotherapy is widely used as first-line treatment for advanced NSCLC, but its benefit in patients with low PD-L1 expression remains uncertain. This study evaluated pembrolizumab plus chemotherap... ...
